1 / 20

Stability of Antimalarial Preparations

Stability of Antimalarial Preparations. Rutendo Kuwana. Accra, December 2009. PQ: Artemisin-derivative issues. No innovator FPP registered in the ICH region. Therefore No comparator available for: Pharmaceutical equivalence studies Bioequivalence studies

spiro
Télécharger la présentation

Stability of Antimalarial Preparations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Stability of Antimalarial Preparations Rutendo Kuwana Accra, December 2009

  2. PQ: Artemisin-derivative issues • No innovator FPP registered in the ICH region. Therefore No comparator available for: • Pharmaceutical equivalence studies • Bioequivalence studies • The APIs and FPPs not official in the internationally used major pharmacopoeias • WHO guides/SOPs apply to multisource FPPs. ICH guides therefore used

  3. Expression of Interest – oral dosage forms • Artesunate*+ Amodiaquine • Artemether*+Lumefantrine* • Artesunate*+ Mefloquine • Artesunate*+ SP (sulphadoxine / pyrimethamine) • Dihydroartemisin+Piperaquine Phosphate* *No comparator at the beginning *High quality-risk API + ... FDC or co-blistered (co-packaged) FPPs * No comparator to date

  4. EOI – other dosage forms • Artemether Injection and rectal FPPs • Artemotil (arteether) Injection • Artesunate Injection and rectal FPPs Only FPPs listed in the EOI will be discussed.

  5. Availability of monographs for drug substances - International Pharmacopoeia • Artemether • Artemisinin • Artemotil • Artenimol • Artesunate • Mefloquine Hydrochloride • Proguanil Hydrochloride – Also in BP • Amodiaquine and Amodiaquine Hydrochloride – Also in USP

  6. International quality standards • Lumefantrine • Pyrimethamine BP, PhEur, PhInt, USP • Sulphadoxine BP, PhEur, PhInt, USP • Piperaquine • Dihydroartemisinin

  7. Other Antimalarial API • APIs described in monographs of major international pharmacopoeias ( 10 years) • Chloroquine, Dapsone, Quinine, Mefloquine, Trimethoprim • APIs not described in monographs of major international pharmacopoeias • Chlorproguanil,, Naphthoquine, Pyronaridine

  8. Properties of Artemisinin derivatives 8 9 7 8a 10 11 12a 6 12 5a 5 1 3 4 2 • Artemisinin(C15H22O5) • 7 centres of asymmetry • 27 potential isomers • One isomer in biosynthesis • Chemical synthesis • Feasible • Economically unacceptable • Chemical derivatization at C-10 (carbonyl-moiety)converts C-10 into an additional stereoisomeric center: • a- and b-isomers are formed

  9. Artemisinin Active antimalarial constituent of the traditional Chinese medicinal herb Artemisia annua L., Compositae Although Artemisinin has seven (7) centers of assymetry Artemisia annua makes only one configuration Practically insoluble in water The bond energy of the O-O bond is ~30 kcal/mol When the peroxide comes into contact with high iron concentrations, the molecule becomes unstable and "explodes" into free radicals. The API, the capsules and the tablets are official in the Ph. Int. Not included in the current EOI.

  10. Artesunate Very slightly soluble in water The ester linkage is inalpha configuration. Both the API and the tablets are official in the Ph. Int. Two functional groups are liable to decomposition

  11. Metabolism of Artemether and Artesunate

  12. Mefloquine hydrochloride Has an optically active carbon Very slightly soluble in water Has no reactive functional groups under general environmental conditions

  13. Pharmaceutical information • Artemisinin derivatives may have α- or β-configurationand each of them can exist in two conformations. The literature does not reveal any impact of the geometric isomerism on efficacy, safety or quality of artemisinins. • The internal peroxide bound is the most reactive part of the molecule. When the peroxide comes into contact with high iron concentrations, the molecule becomes unstable and "explodes" into free radicals. • The ester bond of artesunate is liable to hydrolysis. • The non-artemisinin APIs in the EoI are chemically stable.

  14. Potential impurities of Artemisinins • Starting material (extracted from herbal sources) Starting materials from vegetable origin should be fully characterized and a contaminant profile should be established

  15. Potential impurities of Artemisinins II • Impurities contained in the "starting material" Artemisinin • Biosynthetic by-products • Arteannuin B , Artemisitene, Artemisinic acid, • Extraction from fresh leaves with CHCl3 • Thujone (?) • Cultivation reagents • Pesticide residues, fumigants, mycotoxins • Solvents from the extraction process • Hexane, benzene, acetonitril, ether, pentane, chloroforme…..(?) diesel, fuel (?) [ICH Q3A (R)]

  16. Potential impurities of Artemisinins III • Unreacted starting material • Artemisinin (starting material for derivatives) • Artemisinic acid (starting material for dihydroartemisinin) • Dihydroartemisinin (starting material for derivatives) • …. • Unreacted intermediates, by-products • a-Arthemether, a-Artheether • a/b-Dihydroartemisinin • b-Artesunate

  17. Potential impurities of Artemisinins IV • Reagents, catalysts, residual solvents • Methanol, acetonitril, chloroforme, acetone … • NaBH4, succinic acid/anhydride, triethylamine, dimethylaminopyridine • Degradants • Stability of • ester-derivative (Artesunate) • ether-derivative (Artemether, Arteether) • lactone (Artemisinin) • Stability of artenimol (oxidation) • Susceptibility of endoperoxide bond to reduction • Deoxyartemisinine (loss of active principle)

  18. Compatibility of the API with excipients and diluents • Select innovator excipients (WHOPAR, EPAR) • Magnesium stearate is incompatible with salts of weak bases and strong acids (e.g. Amodiaquine.2HCl) because the formed MgCl2 is highly hygroscopic and, as a result, its lubricant properties also change. • The compatibility and in-use stabilityof the FPP with reconstitution diluentsshould be addressed, e.g. in Artesunate injection.

  19. Increase in concentration of API During some stability studies of Artesunate, the assay results were increasing. The hydrolysis may yield artenimol and succinic acid. The latter can justify the increase in assay. The assay method may be considered to be"stability indicating” but not specific. +

  20. Stress Testing • Artesunate • The drug substance degrades readily at heat conditions in extreme of 100ºC, it is also unstable under light conditions and both acid and base conditions by hydrolysis. The α-epimer of dihydroartemesinin is the major degradant under light conditions. • α-Artemether is the major degradant under heat conditions in extreme of 100ºC although both the α and ß epimers of dihydroartemesinin are also significant degradants under this condition.

More Related